
A woman receives a vaccination (Stock image)
(Picture: PA Archive)A new vaccine against the respiratory syncytial virus (RSV) has shown “exceptional” efficacy in advanced clinical trials, drugmaker GlaxoSmithKline has announced.
GSK said its vaccine had shown 82.6 per cent overall efficacy against the disease in a Phase III study, offering hope that a large-scale rollout could prevent thousands of fatalities.